Cargando…

Subclinical Elevation of Plasma C-Reactive Protein and Illusions/Hallucinations in Subjects with Parkinson’s Disease: Case–control Study

BACKGROUND: Though infections are associated with psychotic symptoms, whether or not subclinical inflammation is associated with hallucinations is not known in Parkinson’s disease (PD). PURPOSE: To investigate the association of illusions/hallucinations and plasma CRP levels in PD patients without s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawada, Hideyuki, Oeda, Tomoko, Umemura, Atsushi, Tomita, Satoshi, Hayashi, Ryutaro, Kohsaka, Masayuki, Yamamoto, Kenji, Sudoh, Shinji, Sugiyama, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908859/
https://www.ncbi.nlm.nih.gov/pubmed/24497930
http://dx.doi.org/10.1371/journal.pone.0085886
_version_ 1782301756956344320
author Sawada, Hideyuki
Oeda, Tomoko
Umemura, Atsushi
Tomita, Satoshi
Hayashi, Ryutaro
Kohsaka, Masayuki
Yamamoto, Kenji
Sudoh, Shinji
Sugiyama, Hiroshi
author_facet Sawada, Hideyuki
Oeda, Tomoko
Umemura, Atsushi
Tomita, Satoshi
Hayashi, Ryutaro
Kohsaka, Masayuki
Yamamoto, Kenji
Sudoh, Shinji
Sugiyama, Hiroshi
author_sort Sawada, Hideyuki
collection PubMed
description BACKGROUND: Though infections are associated with psychotic symptoms, whether or not subclinical inflammation is associated with hallucinations is not known in Parkinson’s disease (PD). PURPOSE: To investigate the association of illusions/hallucinations and plasma CRP levels in PD patients without symptomatic infections. METHODS: PD patients not diagnosed as having infections were assessed for illusions and hallucinations using the Parkinson Psychosis Questionnaire (PPQ). It comprises four-domain questions: PPQ-A for sleep problems, PPQ-B for hallucinations/illusions, PPQ-C for delusions, and PPQ-D for disorientation. Assigning patients with ≥1 points in the PPQ-B score to be cases and others as controls, the association of hallucinations/illusions and clinical features (age, sex, duration of PD, Unified Parkinson’s Disease Rating Scale part 3 (UPDRS-3), Mini-Mental State Examination (MMSE) score, sleep disturbance (PPQ-A score) as well as daily doses of L-Dopa, dopamine agonists, amantadine, and selegiline) were analyzed using a case–control design. RESULTS: A total of 111 patients were examined and plasma CRP levels were <0.1–6.0 mg/L. Hallucinations or illusions were detected in 28 (25.2%). There were significant differences in age, UPDRS-3 score, MMSE score, PPQ-A, daily doses of L-Dopa and dopamine agonists and plasma CRP levels between cases and controls. A multivariate logistic regression model revealed that UPDRS-3 scores and plasma CRP levels were significantly associated with hallucinations/illusions with an adjusted odds ratio of 1.96 (95% confidence interval (CI) 1.20–3.20) per 10 points and 1.57 (95% confidence interval 1.13–2.16) per two-fold, respectively. Dividing patients into thirds by CRP levels (≤0.2, 0.3–0.6, ≥0.7 mg/L), the prevalence of hallucinations/illusions was 13.2%, 21.6%, and 41.7%, in the bottom-, middle-, and top-thirds, respectively (for trend p = 0.012). CONCLUSIONS: Subclinical elevation of plasma CRP levels was associated with hallucinations or illusions after adjustment for motor disability, suggesting that subclinical elevations of CRP levels might be an independent risk for hallucinations/illusions.
format Online
Article
Text
id pubmed-3908859
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39088592014-02-04 Subclinical Elevation of Plasma C-Reactive Protein and Illusions/Hallucinations in Subjects with Parkinson’s Disease: Case–control Study Sawada, Hideyuki Oeda, Tomoko Umemura, Atsushi Tomita, Satoshi Hayashi, Ryutaro Kohsaka, Masayuki Yamamoto, Kenji Sudoh, Shinji Sugiyama, Hiroshi PLoS One Research Article BACKGROUND: Though infections are associated with psychotic symptoms, whether or not subclinical inflammation is associated with hallucinations is not known in Parkinson’s disease (PD). PURPOSE: To investigate the association of illusions/hallucinations and plasma CRP levels in PD patients without symptomatic infections. METHODS: PD patients not diagnosed as having infections were assessed for illusions and hallucinations using the Parkinson Psychosis Questionnaire (PPQ). It comprises four-domain questions: PPQ-A for sleep problems, PPQ-B for hallucinations/illusions, PPQ-C for delusions, and PPQ-D for disorientation. Assigning patients with ≥1 points in the PPQ-B score to be cases and others as controls, the association of hallucinations/illusions and clinical features (age, sex, duration of PD, Unified Parkinson’s Disease Rating Scale part 3 (UPDRS-3), Mini-Mental State Examination (MMSE) score, sleep disturbance (PPQ-A score) as well as daily doses of L-Dopa, dopamine agonists, amantadine, and selegiline) were analyzed using a case–control design. RESULTS: A total of 111 patients were examined and plasma CRP levels were <0.1–6.0 mg/L. Hallucinations or illusions were detected in 28 (25.2%). There were significant differences in age, UPDRS-3 score, MMSE score, PPQ-A, daily doses of L-Dopa and dopamine agonists and plasma CRP levels between cases and controls. A multivariate logistic regression model revealed that UPDRS-3 scores and plasma CRP levels were significantly associated with hallucinations/illusions with an adjusted odds ratio of 1.96 (95% confidence interval (CI) 1.20–3.20) per 10 points and 1.57 (95% confidence interval 1.13–2.16) per two-fold, respectively. Dividing patients into thirds by CRP levels (≤0.2, 0.3–0.6, ≥0.7 mg/L), the prevalence of hallucinations/illusions was 13.2%, 21.6%, and 41.7%, in the bottom-, middle-, and top-thirds, respectively (for trend p = 0.012). CONCLUSIONS: Subclinical elevation of plasma CRP levels was associated with hallucinations or illusions after adjustment for motor disability, suggesting that subclinical elevations of CRP levels might be an independent risk for hallucinations/illusions. Public Library of Science 2014-01-31 /pmc/articles/PMC3908859/ /pubmed/24497930 http://dx.doi.org/10.1371/journal.pone.0085886 Text en © 2014 Sawada et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Sawada, Hideyuki
Oeda, Tomoko
Umemura, Atsushi
Tomita, Satoshi
Hayashi, Ryutaro
Kohsaka, Masayuki
Yamamoto, Kenji
Sudoh, Shinji
Sugiyama, Hiroshi
Subclinical Elevation of Plasma C-Reactive Protein and Illusions/Hallucinations in Subjects with Parkinson’s Disease: Case–control Study
title Subclinical Elevation of Plasma C-Reactive Protein and Illusions/Hallucinations in Subjects with Parkinson’s Disease: Case–control Study
title_full Subclinical Elevation of Plasma C-Reactive Protein and Illusions/Hallucinations in Subjects with Parkinson’s Disease: Case–control Study
title_fullStr Subclinical Elevation of Plasma C-Reactive Protein and Illusions/Hallucinations in Subjects with Parkinson’s Disease: Case–control Study
title_full_unstemmed Subclinical Elevation of Plasma C-Reactive Protein and Illusions/Hallucinations in Subjects with Parkinson’s Disease: Case–control Study
title_short Subclinical Elevation of Plasma C-Reactive Protein and Illusions/Hallucinations in Subjects with Parkinson’s Disease: Case–control Study
title_sort subclinical elevation of plasma c-reactive protein and illusions/hallucinations in subjects with parkinson’s disease: case–control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908859/
https://www.ncbi.nlm.nih.gov/pubmed/24497930
http://dx.doi.org/10.1371/journal.pone.0085886
work_keys_str_mv AT sawadahideyuki subclinicalelevationofplasmacreactiveproteinandillusionshallucinationsinsubjectswithparkinsonsdiseasecasecontrolstudy
AT oedatomoko subclinicalelevationofplasmacreactiveproteinandillusionshallucinationsinsubjectswithparkinsonsdiseasecasecontrolstudy
AT umemuraatsushi subclinicalelevationofplasmacreactiveproteinandillusionshallucinationsinsubjectswithparkinsonsdiseasecasecontrolstudy
AT tomitasatoshi subclinicalelevationofplasmacreactiveproteinandillusionshallucinationsinsubjectswithparkinsonsdiseasecasecontrolstudy
AT hayashiryutaro subclinicalelevationofplasmacreactiveproteinandillusionshallucinationsinsubjectswithparkinsonsdiseasecasecontrolstudy
AT kohsakamasayuki subclinicalelevationofplasmacreactiveproteinandillusionshallucinationsinsubjectswithparkinsonsdiseasecasecontrolstudy
AT yamamotokenji subclinicalelevationofplasmacreactiveproteinandillusionshallucinationsinsubjectswithparkinsonsdiseasecasecontrolstudy
AT sudohshinji subclinicalelevationofplasmacreactiveproteinandillusionshallucinationsinsubjectswithparkinsonsdiseasecasecontrolstudy
AT sugiyamahiroshi subclinicalelevationofplasmacreactiveproteinandillusionshallucinationsinsubjectswithparkinsonsdiseasecasecontrolstudy